Deletion of β-adrenergic receptor 1, 2, or both leads to different bone phenotypes and response to mechanical stimulation

Journal of Bone and Mineral Research

Volumn 27, Issue 6, 2012, Pages 1252-1262

  Pierroz, Dominique D ^a   Bonnet, Nicolas ^a   Bianchi, Estelle N ^a   Bouxsein, Mary L ^b   Baldock, Paul A ^c   Rizzoli, René ^a   Ferrari, Serge L ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

ADRENERGIC; ISOPROTERENOL; MECHANICAL LOADING; PEAK BONE MASS ACQUISITION

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; I KAPPA B; ISOPRENALINE; OSTEOCLAST DIFFERENTIATION FACTOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; CONTROLLED STUDY; FEMUR; GENE DELETION; MALE; MECHANICAL STIMULATION; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PHENOTYPE; SIGNAL TRANSDUCTION; TIBIA; VERTEBRA; WILD TYPE;

ANIMALS; BIOMECHANICS; BODY COMPOSITION; BONE AND BONES; BONE REMODELING; FEMUR; GENE DELETION; GENE EXPRESSION REGULATION; INSULIN-LIKE GROWTH FACTOR I; ISOPROTERENOL; MALE; MICE; ORGAN SIZE; OSTEOBLASTS; OSTEOGENESIS; PHENOTYPE; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; STRESS, MECHANICAL;

EID: 84861320579     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1594     Document Type: Article

References (52)

1. Seeman E., Pathogenesis of bone fragility in women and men. Lancet. 2002; 359 (9320): 1841-50.
2. Rizzoli R, Bonjour JP, Ferrari SL., Osteoporosis, genetics and hormones. J Mol Endocrinol. 2001; 26 (2): 79-94.
3. Raisz LG., Physiology and pathophysiology of bone remodeling. Clin Chem. 1999; 45 (8 Pt 2): 1353-8.
4. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G., Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000; 100 (2): 197-207.
5. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G., Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002; 111 (3): 305-17.
6. Young JB, Landsberg L., Diminished sympathetic nervous system activity in genetically obese (ob/ob) mouse. Am J Physiol. 1983; 245 (2): E148-54.
7. Hamrick MW, Pennington C, Newton D, Xie D, Isales C., Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone. 2004; 34 (3): 376-83.
8. Reid IR., Leptin deficiency-lessons in regional differences in the regulation of bone mass. Bone. 2004; 34 (3): 369-71.
9. Togari A, Arai M, Mizutani S, Koshihara Y, Nagatsu T., Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci Lett. 1997; 233 (2-3): 125-8.
10. Moore RE, Smith CK 2nd, Bailey CS, Voelkel EF, Tashjian AH Jr., Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner. 1993; 23 (3): 301-15.
11. Kellenberger S, Muller K, Richener H, Bilbe G., Formoterol and isoproterenol induce c-fos gene expression in osteoblast-like cells by activating beta2-adrenergic receptors. Bone. 1998; 22 (5): 471-8.
12. Togari A, Arai M, Mogi M, Kondo A, Tsuboi T, Takeuchi T, Yamamoto S, Koshihara Y., Expression mRNAs for neuropeptide receptors, adrenergic receptors, neurotrophins and semaphorin III in human osteoblasts and osteoclasts. In:, Kato T, editor. Frontiers of the mechanisms of memory and dementia. Amsterdam: Elsevier; 2000. p. 163-4.
13. Arai M, Nagasawa T, Koshihara Y, Yamamoto S, Togari A., Effects of beta-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim Biophys Acta. 2003; 1640 (2-3): 137-42.
14. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G., Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005; 434 (7032): 514-20.
15. Takeuchi T, Tsuboi T, Arai M, Togari A., Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem Pharmacol. 2001; 61 (5): 579-86.
16. Kajimura D, Hinoi E, Ferron M, Kode A, Riley KJ, Zhou B, Guo XE, Karsenty G., Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual. J Exp Med. 2011; 208 (4): 841-51.
17. Bouxsein ML, Devlin MJ, Glatt V, Dhillon H, Pierroz DD, Ferrari SL., Mice lacking beta-adrenergic receptors have increased bone mass but are not protected from deleterious skeletal effects of ovariectomy. Endocrinology. 2009; 150 (1): 144-52.
18. Zeman RJ, Hirschman A, Hirschman ML, Guo G, Etlinger JD., Clenbuterol, a beta 2-receptor agonist, reduces net bone loss in denervated hindlimbs. Am J Physiol. 1991; 261 (2 Pt 1): E285-9.
19. Levasseur R, Barrios R, Elefteriou F, Glass DA 2nd, Lieberman MW, Karsenty G., Reversible skeletal abnormalities in gamma-glutamyl transpeptidase-deficient mice. Endocrinology. 2003; 144 (7): 2761-4.
20. Kondo H, Nifuji A, Takeda S, Ezura Y, Rittling SR, Denhardt DT, Nakashima K, Karsenty G, Noda M., Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J Biol Chem. 2005; 280 (34): 30192-200.
21. Baek K, Bloomfield SA., Beta-adrenergic blockade and leptin replacement effectively mitigate disuse bone loss. J Bone Miner Res. 2009; 24 (5): 792-9.
22. Bonnet N, Beaupied H, Vico L, Dolleans E, Laroche N, Courteix D, Benhamou CL., Combined effects of exercise and propranolol on bone tissue in ovariectomized rats. J Bone Miner Res. 2007; 22 (4): 578-88.
23. Marenzana M, De Souza RL, Chenu C., Blockade of beta-adrenergic signaling does not influence the bone mechano-adaptive response in mice. Bone. 2007; 41 (2): 206-15.
24. Rohrer DK, Chruscinski A, Schauble EH, Bernstein D, Kobilka BK., Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. J Biol Chem. 1999; 274 (24): 16701-8.
25. Bouxsein ML, Pierroz DD, Glatt V, Goddard DS, Cavat F, Rizzoli R, Ferrari SL., beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J Bone Miner Res. 2005; 20 (4): 635-43.
26. Ferrari SL, Pierroz DD, Glatt V, Goddard DS, Bianchi EN, Lin FT, Manen D, Bouxsein ML., Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. Endocrinology. 2005; 146 (4): 1854-62.
27. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR., Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2 (6): 595-610.
28. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC., Growth hormone and bone. Endocr Rev. 1998; 19 (1): 55-79.
29. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D., Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002; 110 (6): 771-81.
30. Mohan S, Richman C, Guo R, Amaar Y, Donahue LR, Wergedal J, Baylink DJ., Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms. Endocrinology. 2003; 144 (3): 929-36.
31. Huang HH, Brennan TC, Muir MM, Mason RS., Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009; 220 (1): 267-75.
32. Nance DM, Sanders VM., Autonomic innervation and regulation of the immune system (1987-2007). Brain Behav Immun. 2007; 21 (6): 736-45.
33. Donahue LR, Beamer WG., Growth hormone deficiency in 'little' mice results in aberrant body composition, reduced insulin-like growth factor-I and insulin-like growth factor-binding protein-3 (IGFBP-3), but does not affect IGFBP-2, -1 or -4. J Endocrinol. 1993; 136 (1): 91-104.
34. Holmes SJ, Shalet SM., Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Horm Res. 1996; 45 (1-2): 86-93.
35. Linkhart TA, Mohan S., Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-I) and IGF-II from neonatal mouse calvaria in organ culture. Endocrinology. 1989; 125 (3): 1484-91.
36. Reed BY, Zerwekh JE, Sakhaee K, Breslau NA, Gottschalk F, Pak CY., Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis. J Bone Miner Res. 1995; 10 (8): 1218-24.
37. Rosen CJ, Donahue LR., Insulin-like growth factors and bone: the osteoporosis connection revisited. Proc Soc Exp Biol Med. 1998; 219 (1): 1-7.
38. Kawai M, Rosen CJ., The IGF-I regulatory system and its impact on skeletal and energy homeostasis. J Cell Biochem. 2010; 111 (1): 14-9.
39. Daftary SS, Boudaba C, Tasker JG., Noradrenergic regulation of parvocellular neurons in the rat hypothalamic paraventricular nucleus. Neuroscience. 2000; 96 (4): 743-51.
40. Krieg RJ, Perkins SN, Johnson JH, Rogers JP, Arimura A, Cronin MJ., Beta-adrenergic stimulation of growth hormone (GH) release in vivo, and subsequent inhibition of GH-releasing factor-induced GH secretion. Endocrinology. 1988; 122 (2): 531-7.
41. McWilliam JR, Meldrum BS., Noradrenergic regulation of growth hormone secretion in the baboon. Endocrinology. 1983; 112 (1): 254-9.
42. Alarcõn P, Núñez L, García-Sancho J., Direct actions of adrenergic agents on rat anterior pituitary cells. Pflugers Arch. 2001; 442 (6): 834-41.
43. Suzuki J, Ohno I, Nawata J, Miura S, Ikeda J, Shirato K., Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. J Cardiovasc Pharmacol. 1999; 34 (5): 635-44.
44. Dawson JM, Craigon J, Buttery PJ, Beever DE., Influence of diet and beta-agonist administration on plasma concentrations of growth hormone and insulin-like growth factor-1 in young steers. Br J Nutr. 1993; 70 (1): 93-102.
45. Marenzana M, Chenu C., Sympathetic nervous system and bone adaptive response to its mechanical environment. J Musculoskelet Neuronal Interact. 2008; 8 (2): 111-20.
46. Baker JG, Hall IP, Hill SJ., Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor. Mol Pharmacol. 2003; 63 (6): 1312-21.
47. Lean JM, Jagger CJ, Chambers TJ, Chow JW., Increased insulin-like growth factor I mRNA expression in rat osteocytes in response to mechanical stimulation. Am J Physiol. 1995; 268 (2 Pt 1): E318-27.
48. Reijnders CM, Bravenboer N, Holzmann PJ, Bhoelan F, Blankenstein MA, Lips P., In vivo mechanical loading modulates insulin-like growth factor binding protein-2 gene expression in rat osteocytes. Calcif Tissue Int. 2007; 80 (2): 137-43.
49. Reijnders CM, Bravenboer N, Tromp AM, Blankenstein MA, Lips P., Effect of mechanical loading on insulin-like growth factor-I gene expression in rat tibia. J Endocrinol. 2007; 192 (1): 131-40.
50. Rejnmark L, Vestergaard P, Kassem M, Christoffersen BR, Kolthoff N, Brixen K, Mosekilde L., Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int. 2004; 75 (5): 365-72.
51. Rejnmark L, Vestergaard P, Mosekilde L., Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens. 2006; 24 (3): 581-9.
52. Reid IR., Effects of beta-blockers on fracture risk. J Musculoskelet Neuronal Interact. 2008; 8 (2): 105-10.